ALZAMEND NEURO, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
ALZAMEND NEURO, INC. (ALZN) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 1.73 million shares for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-09-10
- ALZAMEND NEURO, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-07-31 was 1.73M shares, a 1055.69% increase year-over-year.
- ALZAMEND NEURO, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-10-31 was 149.91K shares, a 36.21% increase year-over-year.
- ALZAMEND NEURO, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-07-31 was 149.91K shares, a 142.64% increase year-over-year.
- ALZAMEND NEURO, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-10-31 was 110.06K shares.
- ALZAMEND NEURO, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2026 was 1.73M shares, a 1056.05% increase from fiscal 2025.
- ALZAMEND NEURO, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 149.91K shares, a 271.60% increase from fiscal 2024.
- ALZAMEND NEURO, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 40.34K shares, a 78.66% decline from fiscal 2023.
- ALZAMEND NEURO, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 189.05K shares, a 99.34% decline from fiscal 2022.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-07-31 | 1.73M shares 10-Q · filed 2026-09-10 | |||||||
| 2026-04-30 | 1.73M shares 10-K · filed 2026-07-22 | |||||||
| 2026-01-31 | 149.81K shares 10-Q · filed 2026-03-11 | |||||||
| 2025-10-31 | 149.91K shares 10-Q · filed 2025-12-09 | |||||||
| 2025-07-31 | 149.91K shares 10-Q · filed 2026-09-10 | |||||||
| 2025-04-30 | 149.91K shares 10-K · filed 2026-07-22 | |||||||
| 2025-01-31 | 110.06K shares 10-Q · filed 2026-03-11 | 990.53K shares 10-Q · filed 2025-03-10 | ||||||
| 2024-10-31 | 110.06K shares 10-Q · filed 2025-12-09 | 990.53K shares 10-Q · filed 2024-12-11 | ||||||
| 2024-07-31 | 61.78K shares 10-Q · filed 2025-09-10 | 556.04K shares 10-Q · filed 2024-09-11 | ||||||
| 2024-04-30 | 40.34K shares 10-K · filed 2025-07-22 | 360.95K shares 10-K · filed 2024-07-30 | ||||||
| 2024-01-31 | 277.63K shares 10-Q · filed 2025-03-10 | 2.78M shares 10-Q · filed 2024-03-25 | ||||||
| 2023-10-31 | 188.97K shares 10-Q · filed 2024-12-11 | 1.89M shares 10-Q · filed 2023-12-15 | ||||||
| 2023-07-31 | 189.05K shares 10-Q · filed 2024-09-11 | 28.36M shares 10-Q · filed 2023-09-13 | ||||||
| 2023-04-30 | 189.05K shares 10-K · filed 2024-07-30 | 28.36M shares 10-K · filed 2023-07-27 | ||||||
| 2023-01-31 | 1.89M shares 10-Q · filed 2024-03-25 | 28.31M shares 10-Q · filed 2023-03-15 | ||||||
| 2022-10-31 | 2.37M shares 10-Q · filed 2023-12-15 | 27.31M shares 10-Q · filed 2022-12-12 | ||||||
| 2022-07-31 | 28.82M shares 10-Q · filed 2023-09-13 | 28.75M shares 10-Q · filed 2022-09-13 | ||||||
| 2022-04-30 | 28.82M shares 10-K · filed 2023-07-27 | 24.04M shares 10-K · filed 2022-07-19 | ||||||
| 2022-01-31 | 22.33M shares 10-Q · filed 2023-03-15 | |||||||
| 2021-10-31 | 22.56M shares 10-Q · filed 2022-12-12 | |||||||
| 2021-07-31 | 41.56M shares 10-Q · filed 2022-09-13 | 27.01M shares 10-Q · filed 2021-09-13 | ||||||
| 2021-04-30 | 38.32M shares 10-K · filed 2022-07-19 | 40.08M shares 10-K · filed 2021-07-29 | ||||||
| 2021-01-31 | 38.32M shares 10-Q · filed 2022-03-15 | |||||||
| 2020-10-31 | 38.28M shares 10-Q · filed 2021-12-13 | |||||||
| 2020-07-31 | 37.83M shares 10-Q · filed 2021-09-13 | |||||||
| 2020-04-30 | 37.83M shares 10-K · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |